Skip to main content

Top Menu

  • Contact
  • Media
  • Careers
  • Staff
  • About Us
    • About CCTG
    • Committee Leadership
    • CCTG Scientific Leadership
    • CCTG Management
    • Careers at CCTG
    • CCTG policies
    • Contact us
  • Patients & Families
    • Patients & Families
    • Patient Representatives Committee
    • Patients as research partners
    • Resources for patients & families
    • Clinical trials - public
  • Disease Site Listings - Public

    Disease Site Listings - Public

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Multi-Site
    • Sarcoma
    • Symptom Control
  • Disease Site Listings - Members

    Disease Site Listings - Members

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
  • Clinical Trials
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Clinical trials - overview
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Publications

    Mobile CCTG Clinical Trials

    • Member Trial Pages
    • Public Trial Pages
    • Publications
    The Impact of the COVID-19 on Canadians Living with Cancer

    CCTG SC27 - The Impact of the COVID-19 on Canadians Living with Cancer

    CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.

    More >>

    Recently Activated Trials

    I240

    Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

    More >>

    I240A

    A Study of Durvalumab and BA3011 in Patients with Advanced Ovarian Cancer that is Resistant to Platinum Based Chemotherapy

    More >>

    I240B

    A Study of Durvalumab and BA3021 in Patients with Advanced Ovarian Cancer that is Resistant to Platinum Based Chemotherapy

    More >>

    PAC3

    Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer

    More >>
  • Member Resources

    Member Links

    • Current Trial pages
    • Become a member
    • Toolbox
    • Funding information
    • Compliance and oversight
    • Audit, inspection & partner compliance
    • Generic protocols
    • Standing committees
    • Disease site & IND committees
    • Terms of reference
    • Group newsletter: CCTG Connection
    • Help & Support
    Practice changing OlympiA (CCTG MA36) trial results

    ASCO 2021 Plenary - Practice changing OlympiA (CCTG MA36) trial results

    Giving olaparib to patients with certain BRCA-mutated breast cancer for 1 year after they were treated with chemotherapy, surgery, or radiation significantly improved disease-free survival, according to the results that were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were simultaneously published in the New England Journal of Medicine.

    More >>

    Planned Trials

    CLC3

    Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL (EVOLVE)

    EN10

    Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)

    GA4

    Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Overexpressing Advanced Gastroesophageal Adenocarcinoma

    HD11

    Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

    More >>

    HN11

    SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

    HN12

    PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)

    MA41

    De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)

    MAC27

    COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

    MAC28

    De-escalation of Breast Radiation for Conservative Treatment of Stage 1, HR+, HER2 -, RS

    MYC2

    Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)

    More >>

    Disease Site Committees

    • Brain
    • Breast
    • Gastro-Intestinal
    • Gynecologic
    • Genito-Urinary
    • Head & Neck Working Group
    • Hematologic
    • IND
    • IND Executive
    • Lung Disease
    • Melanoma
    • Sarcoma
  • Meetings & Education
  • Search

  • Donate
  • Toolbox
    • Applications
    • >>  EDC (Medidata Rave)
    • >>  iMedidata
    • >>  Mango
    • >>  Ripple
    • >>  Lettuce
    • >>  Sprout (ePRO)
    • Exposure Reporting
    • >>  CTEP website
    • >>  CTCAE v5.0 booklet
    • >>  CTCAE v4.0 booklet
    • >>  CTCAE v3.0 booklet
    • >>  CTEP-AERS reporting
    • >>  EDC SAE (paper report)
    • >>  Pregnancy reporting form
    • >>  Exposure reporting form
    • Support
    • >>  Passwords management
    • >>  CCTG contacts
    • >>  Support information
    • Tissue Bank
    • >>  Tissue Bank
    • >>  Inventory
    • >>  Tissue research
    • Reports
    • >>  Accrual utility (Monthly site accrual)
    • >>  Safety reports
    • >>  Papaya
    • >>  Ethics
    • >>  Trial closure
    • Data Management
    • >>  Baseline symptoms & adverse events
    • >>  Concomitant medications template
    • >>  SI conversion table
    • >>  iRECIST & RECIST guidelines
    • Training
    • >>  NIH ethics training
    • >>  Division 5 part C
    • >>  Good clinical practice
    • >>  Site training
    • >>  Supplementary training
  • Contact Us
  • Media
  • Staff

  For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Staff Links

Email

Zimbra

Messenger Express

Intranet

CCTG Intranet

 

Instructions for Working at Home

Working at Home

File Sharing

Nextcloud

  • Partnerships 500+ trials in 40+ countries
  • IND Program 36+ years experience in 205+ drug trials
  • Tissue Bank 300,000+ samples from 120+ trials
  • Network 2100+ investigators at 85+ sites
  • Become a CCTG Investigator
Career Opportunities

Footer Menu

  • About us
  • Patients & Families
  • Clinical trials
  • Member resources
  • Meetings & Education
  • Publications
  • Toolbox
  • Contact us
  • Media centre
  • Staff
  • Careers

CANADIAN CANCER TRIALS GROUP

Cancer Research Institute
Queen's University

10 Stuart Street
Kingston, Ontario
Canada K7L 3N6

A NATIONAL PROGRAM OF THE:

 

OPERATIONS AND STATISTICAL CENTRE LOCATED AT:

PROUDLY AFFILIATED WITH:

As a national cooperative group, CCTG recognizes that Canada is situated on Indigenous lands, we acknowledge that the Operations and Statistics Centre, located at Queen’s University, is located on traditional Anishinaabe and Haudenosaunee Territory.
© Canadian Cancer Trials Group, 2021 | Terms & Conditions Facebook LinkedIn TwitterYouTube